Bolt Biotherapeutics, Inc. (BOLT) Dividend History

Bolt Biotherapeutics, Inc. is a biotechnology company focused on developing tumor-activated immunotherapies. They utilize their proprietary Amplify-They-Cell platform to design therapies that activate the immune system specifically within the tumor microenvironment, aiming to enhance cancer treatment efficacy while minimizing systemic side effects.

900 Chesapeake Drive, Redwood City, CA, 94063
Phone: 650-665-9295
Website: https://www.boltbio.com

Dividend History

Bolt Biotherapeutics, Inc. currently does not pay dividends

Company News

  • Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

    Bolt Biotherapeutics announced positive results from a Phase 1 study of its cancer immunotherapy BDC-3042, which showed favorable safety, biological activity, and signs of anti-tumor activity. The company is seeking a partner to advance the development of BDC-3042.

    GlobeNewswire Inc.
  • Bolt Biotherapeutics faces Nasdaq delisting risk By Investing.com - Investing.com Australia

    Bolt Biotherapeutics, a pharmaceutical company, has been notified by Nasdaq of non-compliance with the exchange's minimum bid price requirement. The company has been given a grace period to regain compliance, but if it fails to do so, its stock could be delisted from the exchange.

    Investing.com
  • This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Today

    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Deutsche Bank analyst Bryan Keane downgraded the rating on Accenture plc (NYSE:ACN) from Buy to Hold, while slashing the price target from $409 to $295. Accenture shares declined 0.2% to close at $306.95 on Tuesday. See how other analysts view this stock. Stifel analyst Stephen Willey downgraded Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) from Buy to Hold and lowered the price target from $6 to $1.5. Bolt Biotherapeutics shares slipped ...Full story available on Benzinga.com

    Benzinga
    Featured Companies: ACN AMRK SPWR
  • Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates

    Prothena (PRTA) delivered earnings and revenue surprises of -10.74% and 98.67%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: PRTA
Page data last updated 07/23/2025 17:03:45 UTC